AMERICAN BIOMED, Minimally Invasive Technology (ABMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Fisher who wrote (1424)	7/9/1998 12:30:00 PM
From: Jeffrey L. Henken	Read Replies (2) of 2887

Today AVEI acquired Bard's coronary catheter business. On the surface this might look like something very bad for ABMI shareholders who have been hoping AVEI might acquire ABMI. Please read the news release carefully and then reread the ABMI profile prepared by Coffin Communications: biz.yahoo.com Bard's line and American BioMed's product line have very little, if any overlap. ABMI is still very much a likely buyout candidate for any number of the larger companies in the minimally invasive surgical area, including AVEI. Remember AVEI also bought World Medical back in April. That deal was not a cash transaction but a stock swap transaction: biz.yahoo.com AVEI is still free to make these kinds of deals with smaller companies like ABMI if they choose to do so. I think it is more than just a possibility that we will see ABMI either bought out or form one or more strategic partnerships with another company in this field in 1998. Please take the time to pick up the phone and call someone at American BioMed. Even phoning AVEI like I have done is educational and it will make you feel a lot better about holding your ABMI shares. Remember neither JNJ or AVEI has an atherectomy device. They don't have a complete line of 100% silicone catheters for peripheral indications. They don't have the MicroFilter Guidewire or the 27 patents protecting ABMI's technology like the OmniStent. If you have not read these posts yet you should because American BioMed is a much better company today than the stock price reflects: American BioMed due diligence: Message 5111992 American BioMed Company Profile: Message 5134341 Please take the time to call either Steve Rash, CEO of American BioMed or Christi Mottola at Coffin Communications. The stock will be headed up again soon and buy days like this one will be only a memory. There are lots of good things happening in this field. Many stocks are doing well. ABMI will see it's day in the sun too. American BioMed Inc. Steven B. Rash, 281/367-3895 Coffin/Mottola Communications Christi Mottola, 714/851-1109 As I said even talking to Diane Lefebrve at AVEI was quite informative. I still really like that company even if they never acquire or form a strategic partnership with ABMI: (707) 525-0111 Regards, Jeff

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next